AnaptysBio, Inc. (NASDAQ:ANAB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
Several other analysts also recently issued reports on the company. Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada upped their price objective on AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday. Credit Suisse Group upped their price objective on AnaptysBio from $38.00 to $85.00 in a research report on Tuesday. JMP Securities upped their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Stifel Nicolaus restated a “buy” rating and issued a $35.00 price objective on shares of AnaptysBio in a research report on Tuesday, September 12th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $59.14.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $3.45 million.
TRADEMARK VIOLATION WARNING: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/10/13/zacks-investment-research-downgrades-anaptysbio-inc-anab-to-hold.html.
In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares in the company, valued at $40,862,344.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. Insiders sold 1,133,940 shares of company stock valued at $24,223,316 over the last quarter.
A number of large investors have recently made changes to their positions in ANAB. Perceptive Advisors LLC acquired a new stake in AnaptysBio during the first quarter worth about $24,474,000. Marshall Wace North America L.P. acquired a new stake in AnaptysBio during the first quarter worth about $6,924,000. MARSHALL WACE ASIA Ltd acquired a new stake in AnaptysBio during the first quarter worth about $6,924,000. Artal Group S.A. increased its stake in AnaptysBio by 459.4% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after acquiring an additional 205,310 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in AnaptysBio during the first quarter worth about $3,851,000. Institutional investors own 71.35% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.